These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 3802708)

  • 1. The effect of coadministration of verapamil on the pharmacokinetics and metabolism of quinidine.
    Edwards DJ; Lavoie R; Beckman H; Blevins R; Rubenfire M
    Clin Pharmacol Ther; 1987 Jan; 41(1):68-73. PubMed ID: 3802708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of verapamil on antipyrine pharmacokinetics and metabolism in man.
    Bach D; Blevins R; Kerner N; Rubenfire M; Edwards DJ
    Br J Clin Pharmacol; 1986 Jun; 21(6):655-9. PubMed ID: 3741715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quinidine does not alter antipyrine metabolism.
    Bowles SK; Cardozo L; Edwards DJ
    J Clin Pharmacol; 1990 Mar; 30(3):267-71. PubMed ID: 2312782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impairment of digoxin clearance by coadministration of quinidine.
    Ochs HR; Bodem G; Greenblatt DJ
    J Clin Pharmacol; 1981 Oct; 21(10):396-400. PubMed ID: 7309901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of effect of cimetidine on the metabolism of quinidine: effect on renal clearance.
    Hardy BG; Schentag JJ
    Int J Clin Pharmacol Ther Toxicol; 1988 Aug; 26(8):388-91. PubMed ID: 3220613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quinidine as a probe for CYP3A4 activity: intrasubject variability and lack of correlation with probe-based assays for CYP1A2, CYP2C9, CYP2C19, and CYP2D6.
    Damkier P; Brøsen K
    Clin Pharmacol Ther; 2000 Aug; 68(2):199-209. PubMed ID: 10976551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of effect of smoking on the metabolism and pharmacokinetics of quinidine in patients.
    Edwards DJ; Axelson JE; Visco JP; vanEvery S; Slaughter RL; Lalka D
    Br J Clin Pharmacol; 1987 Mar; 23(3):351-4. PubMed ID: 3567051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and metabolism of quinidine in extensive and poor metabolisers of sparteine.
    Mikus G; Ha HR; Vozeh S; Zekorn C; Follath F; Eichelbaum M
    Eur J Clin Pharmacol; 1986; 31(1):69-72. PubMed ID: 3780830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vitreal kinetics of quinidine in rabbits in the presence of topically coadministered P-glycoprotein substrates/modulators.
    Majumdar S; Hippalgaonkar K; Srirangam R
    Drug Metab Dispos; 2009 Aug; 37(8):1718-25. PubMed ID: 19406953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of quinidine, verapamil and nifedipine on the pharmacokinetics and pharmacodynamics of digitoxin during steady state conditions.
    Kuhlmann J
    Arzneimittelforschung; 1987 May; 37(5):545-8. PubMed ID: 3619976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinetics and dynamics of quinidine-N-oxide in healthy subjects.
    Ha HR; Vozeh S; Uematsu T; Guentert TW; Follath F
    Clin Pharmacol Ther; 1987 Sep; 42(3):341-5. PubMed ID: 3621790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of ciprofloxacin on the pharmacokinetic and ECG parameters of quinidine.
    Bleske BE; Carver PL; Annesley TM; Bleske JR; Morady F
    J Clin Pharmacol; 1990 Oct; 30(10):911-5. PubMed ID: 2229451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of coadministration of verapamil and quinidine on serum digoxin concentration.
    Doering W
    Eur J Clin Pharmacol; 1983; 25(4):517-21. PubMed ID: 6653647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pharmacokinetics and pharmacodynamics of quinidine and 3-hydroxyquinidine.
    Wooding-Scott RA; Smalley J; Visco J; Slaughter RL
    Br J Clin Pharmacol; 1988 Oct; 26(4):415-21. PubMed ID: 3190991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elimination kinetic of high polar metabolites pool of quinidine from human serum.
    Camsonne R; Moulin MA; Charbonneau P; Bazin C
    Int J Clin Pharmacol Ther Toxicol; 1985 Feb; 23(2):74-5. PubMed ID: 3988396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in antipyrine and indocyanine green kinetics during nifedipine, verapamil, and diltiazem therapy.
    Bauer LA; Stenwall M; Horn JR; Davis R; Opheim K; Greene L
    Clin Pharmacol Ther; 1986 Aug; 40(2):239-42. PubMed ID: 3731687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Total and unbound concentrations of quinidine and 3-hydroxyquinidine at steady state.
    Wooding-Scott RA; Visco J; Slaughter RL
    Am Heart J; 1987 Feb; 113(2 Pt 1):302-6. PubMed ID: 3812182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinetics and electrocardiographic changes after oral 3-OH-quinidine in healthy subjects.
    Vozeh S; Uematsu T; Guentert TW; Ha HR; Follath F
    Clin Pharmacol Ther; 1985 May; 37(5):575-81. PubMed ID: 3987181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of CYP2D6 by quinidine and its effects on the metabolism of cilostazol.
    Bramer SL; Suri A
    Clin Pharmacokinet; 1999; 37 Suppl 2():41-51. PubMed ID: 10702886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics of the digoxin-quinidine and digoxin-verapamil interactions in the rat kidney.
    Koren G; MacLeod SM
    Res Commun Chem Pathol Pharmacol; 1984 Jul; 45(1):3-18. PubMed ID: 6473899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.